List of Marijuana/Cannabinoid-Derived Drugs Companies with Phase 1 Active Clinical Trial - 5

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Infusing Innovation In Everything We Do Looking for hemp-derived CBD ingredients of the highest quality, purity and consistency? Need a proven source for premium bulk and differentiated finished goods, whose mandate to champion innovation, science and compliance leads the field? Explore how the beneficial properties of CBD can enhance your product’s impact and value — in food and beverage, creams and other topicals, pet products and more. Trust a genuine industry pioneer. Partner with GenCanna. Since our inception in 2014, GenCanna has remained at the vanguard of today’s now booming CBD industry, because our influential founders helped create it. Literally. Vetted, tested and proven over time, this makes us your smartest, surest choice in a full-service CBD partner. Our roots extend back to the earliest days of cannabis legalization and reform. GenCanna helped lead the introduction of Kentucky’s groundbreaking 2014 Hemp Pilot Program. We continue spearheading regulatory initiatives that open and accelerate industry growth. In short, GenCanna has remained at the heart of it all, earning the highest industry certifications, product validations and compliance accreditations to this day. Our scalable, premium-quality derivatives and differentiated finished goods bear witness to GenCanna’s unbridled commitment to excellence: • High-Quality Cannabinoid Isolates and Distillates • Premium Bulk Broad-Spectrum and Full-Spectrum Ingredients • Water-Soluble Liquids and Soluble Powders • Reserve Oils and Bottled Custom Oil Drops • Superior Custom Formulations: -Gummies -Capsules, soft gels, tablets, and other supplement form factors -Food and beverages -Broad range of cosmetics and topicals -Health and wellbeing topicals -Pet products • Turnkey Private Label Programs • White Label Products … you name it, we’ll infuse it! Ready to achieve the next level in CBD success? RELIABLE. INNOVATIVE. GENCANNA. Premium CBD ingredients that formulate profitability for you.

For 85 years, PerkinElmer has pushed the boundaries of science in our food, industrial, life science and environmental markets. In addition to innovative laboratory technologies, our OneSource services division delivers a highly trained, experienced, and collaborative team of service engineers with solutions scalable and customizable to serve laboratory needs. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate better, and create better. PerkinElmer is a leading, global provider of technology and service solutions that help customers measure, quantify, detect, and report in ways that help ensure the quality, safety, and satisfaction of their products. Science with Purpose. Learn more at www.perkinelmer.com.

Phylos is a cannabis genetics company focused on helping growers of all sizes to succeed commercially with seeds that produce the highest quality cannabis in the most cost-effective way. Phylos supports commercial-scale cultivation with the industry's first Production-Ready Seed™: premium, phenotypically stable, fully-feminized F1 hybrid seeds that deliver exceptional flower quality, potency, vigor, and yield. Phylos also leverages its proprietary technologies and its cultivation, extraction, and formulation expertise to provide partners with unparalleled THCV genetics and natural, safe and effective ingredients.

Revive is a life sciences company focused on the research and development of therapeutics for infectious diseases and rare disorders, and it is prioritizing drug development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations.